Does dehydroepiandrosterone (DHEA) improve IVF outcomes in poor responders? A randomised, double-blind, placebo-controlled trial

Homerton University Hospital NHS Foundation Trust (UK)0 个研究点目标入组 400 人开始时间: 2013年10月29日最近更新: 2022年2月21日

适应症

试验速览

暂无简介。

•Current inclusion criteria as of 24/10/2017:
•Inclusion criteria are based on the ESHRE definition of poor responders and would include any patient with any two of the following:
•1. Age = 40 years
•2. Markers for poor ovarian reserve (AMH <7 pmol/L(<1.1 ng/ml) and/or AFC< 7)
•3. Previous poor response to ovarian stimulation ( =3 oocytes with a conventional stimulation protocol)
•Previous inclusion criteria:
•European Society of Human Reproduction and Embryology (ESHRE) criteria for poor responders:
•1. Age > 40 years
•2. Markers for poor ovarian reserve [Anti-Mullerian Hormone (AMH) < 0.5 ng/ml (5 pmol/L), Follicle-Stimulating Hormone (FSH) > 15 IU, Antral Follicle Counts (AFC) < 6]
•3. Previous poor response to ovarian stimulation (less than three mature follicles on day of hCG trigger/cycle cancellation due to poor response/less than three oocytes retrieved)

•Current exclusion criteria as of 24/10/2017:
•1. Women ?42 years
•2. Women with premature ovarian failure/premature menopause (FSH>40 U/L)
•3. Women already taking DHEA.
•4. Patients with a known allergy to the trial drug or any of the active ingredients in the placebo
•Previous exclusion criteria:
•1. Women > 42 years
•2. Women with premature ovarian failure/premature menopause (FSH > 40 U/L)

发起方

Homerton University Hospital NHS Foundation Trust (UK)